MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines

BACKGROUND:The MAP2K1 K57T mutation is known to be a potential mechanism of primary and secondary resistance to EGFR inhibitors in metastatic colorectal cancer (CRC) and has also been reported to promote resistance to BRAF and MEK inhibitors. It is important to overcome therapeutic resistance to EGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, J. E., Kim, K.K., Kim, S. Y., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., Kim, S. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560144/
https://www.ncbi.nlm.nih.gov/pubmed/28819429
http://dx.doi.org/10.7150/jca.19582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560144/
https://www.ncbi.nlm.nih.gov/pubmed/28819429
http://dx.doi.org/10.7150/jca.19582

Ejemplares similares